Panbela announces first patients enrolled in europe for aspire trial studying ivospemin (sbp-101) in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

Minneapolis, nov. 28, 2022 (globe newswire) -- panbela therapeutics, inc . (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced its first patients enrolled in europe for its aspire global clinical trial in the first-line treatment of metastatic pancreatic cancer. aspire is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. detailed information on the trial can be located at  https://clinicaltrials.gov/ct2/show/nct05254171 .
PBLA Ratings Summary
PBLA Quant Ranking